Esperance Pharmaceuticals, Inc., based in Houston, Texas, is a privately held company specializing in the development of a new class of targeted anticancer drugs. These drugs are designed to selectively kill cancer cells by binding to specific receptors on their surface, ensuring minimal harm to normal cells. This targeted approach is particularly effective against cells that are resistant to traditional chemotherapeutic drugs. Esperance has formed a strategic alliance with MD Anderson Cancer Center, a leading cancer treatment and research institution, to accelerate the clinical development of EP 100, a promising treatment for ovarian cancer. The company operates in the oncology market, serving healthcare providers and patients seeking advanced cancer treatments. Esperance's business model focuses on research and development, clinical trials, and strategic partnerships to bring their innovative therapies to market. Revenue is generated through licensing agreements, partnerships, and potential future sales of approved drugs.

Keywords: targeted anticancer drugs, selective killing, cancer cells, normal cells, drug resistance, strategic alliance, MD Anderson, EP 100, ovarian cancer, oncology market.